Atalanta Therapeutics Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
Atalanta Therapeutics is a biotechnology company focused on developing treatments for intractable central nervous system diseases through RNA interference. The company’s core platform uses divalent small interfering RNA (di-siRNA) to achieve durable, selective gene silencing across the brain and spinal cord. It is based in Boston, Massachusetts, and was founded by Anastasia Khvorova, Craig Mello, and Neil Aronin from the RNA Therapeutics Institute at the University of Massachusetts Medical School. Its portfolio includes a wholly owned pipeline targeting Huntington's disease, genetic epilepsy, severe chronic pain, and other neurological conditions, in addition to programs advanced through a collaboration with Genentech. In June 2025, Joanne Kotz was appointed chief executive officer, succeeding Alicia Secor as part of a planned leadership transition.